Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Reduction of HIV in the Central Nervous System
NCT05452564Phase 2Recruiting
- Start
- May 2023
- Primary completion
- Jan 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in human immunodeficiency virus infection (HIV). Started May 2023; status: recruiting.
02
Drugs
baricitinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05452564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05452564.